AbbVie announced that the FDA has approved a new packaging option for AndroGel (testosterone gel) 1.62%. Besides the previously approved metered-dose pump packaging, Androgel 1.62% will also be available in two separate strength packets. Each packet will contain either 20.25mg or 40.5mg of testosterone. The starting dose of Androgel 1.62% is 40.5mg of testosterone.
AndroGel, a Schedule III controlled substance, is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
For more information visit www.abbvie.com.